Finerenone wins FDA clearance for type 1 diabetes–related CKD, lowering albuminuria in FINE-ONE and opening a long-awaited treatment path.
|Slideshows|June 5, 2018
Obesity Briefs from the AACE Annual Scientific & Clinical Congress
Author(s)Gregory M. Weiss, MD
Highlights include: POC A1c testing in prediabetes screening, first-year weight loss after bariatric surgery, and predicting fracture risk in obese patients.
Advertisement
Advertisement
Related to this article
The US FDA cleared a novel insulin patch pump that can be used for up to 3 days with an additional 12-hour grace period in persons with diabetes.
Tirzepatide gained an FDA cardiovascular indication after SURPASS-CVOT showed noninferiority to dulaglutide in high-risk adults.
FDA authorized Abbott’s Libre Duo 10 Day system, the first wearable device to continuously monitor both glucose and ketones.
Insulin icodec is now available in the US after FDA approval, offering adults with type 2 diabetes a once-weekly basal insulin option.
Advertisement
Advertisement
Trending on Patient Care Online
1
Lumateperone Reduces Acute Mania Symptoms in Phase 3 Bipolar I Trial
2
Endocrine Society Obesity Statement Calls for Goals Beyond Weight Loss
3
FDA Approves Finerenone for CKD Associated With Type 1 Diabetes
4
FAQ: What the Endocrine Society’s New Scientific Statement Means for Obesity Treatment
5